Latest Pharma and Biotech News
Pharmaceutical
3 June 2025 The UK risks losing £11 billion ($14 billion) in pharmaceutical R&D investment by 2033 unless urgent reforms are made to high and unpredictable clawback payments imposed on medicine sales to the National Health Service, according to a new report commissioned by the Association of the British Pharmaceutical Industry (ABPI).
Today's issue
Refine Search
Pharmaceutical
Italian drug discovery specialist Axxam and German AI firm Molecular Health have struck a strategic alliance aimed at improving the precision and speed of therapeutic target identification across multiple disease areas. 4 June 2025
Biotechnology
US clinical-stage biotech Vigil Neuroscience today announced a disappointing update on the Phase II IGNITE open-label clinical trial evaluating iluzanebart, a monoclonal antibody TREM2 agonist, for the potential treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP). 4 June 2025
Pharmaceutical
Neuropsychiatric disorders specialist Alto Neuroscience, has entered into an asset purchase agreement with Chase Therapeutics Corporation to buy a portfolio of potentially best-in-class dopamine agonist drug combinations. 4 June 2025
Pharmaceutical
Danish dermatology specialist LEO Pharma has appointed Helle Hedegaard Juhl as executive vice president for global people and corporate affairs (GPCA). 4 June 2025
Pharmaceutical
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has published the UK’s first official guidance to support the safe development and use of phage therapies - treatments that use viruses to target and destroy harmful bacteria. 4 June 2025
Biotechnology
US clinical-stage biotech Sagimet Biosciences today reported denifanstat met all primary and secondary endpoints in a Phase III clinical trial for the treatment of moderate to severe acne vulgaris conducted by Sagimet’s license partner Ascletis Bioscience in China. 4 June 2025
Pharmaceutical
The European Commission (EC) has approved a label extension for Evrysdi (risdiplam) to include a new, room-temperature stable tablet for people living with spinal muscular atrophy (SMA), Swiss pharma giant Roche revealed today 4 June 2025
Pharmaceutical
The American medicines regulator has committed to reviewing the safety of the abortion pill mifepristone, amid renewed political scrutiny and pressure from conservative lawmakers. 4 June 2025
Pharmaceutical
US biotech BioAge Labs is expanding its obesity pipeline just months after shelving its lead drug in the category due to liver toxicity. 4 June 2025
Biotechnology
India’s Zydus Lifesciences announced that it has entered into a definitive agreement with Agenus to acquire India and Sri Lanka commercial rights for its investigational botensilimab (BOT) and balstilimab (BAL), combination therapy. 4 June 2025
Biotechnology
The European Commission (EC) has approved Adcetris (brentuximab vedotin) in combination with etoposide, cyclophosphamide, doxorubicin, dacarbazine and dexamethasone (ECADD) – a chemotherapy regimen – in adult patients with newly diagnosed Stage IIb with risk factors/III/IV Hodgkin lymphoma. 4 June 2025
Pharmaceutical
Sogroya (somapacitan injection) has been recommended by UK health technology assessor the National Institute for Health and Care Excellence (NICE) as a treatment for people aged 3 to 17 years with pediatric growth hormone deficiency, the UK subsidiary of Denmark’s Novo Nordisk revealed yesterday. 4 June 2025
Pharmaceutical
Sweden’s Karolinska Development today revealed that its portfolio company OssDsign has carried out a directed share issue through an accelerated book-building procedure that brought the company approximately 158 million kronor ($16.5 million). 4 June 2025
Pharmaceutical
US pharma major Eli Lilly has struck a deal worth up to $870 million with Swedish biotech Camurus, securing global rights to apply the latter’s extended-release delivery platform to a set of its own metabolic disease compounds. 4 June 2025
Pharmaceutical
The American medicines regulator has approved Bayer’s Nubeqa (darolutamide) for broader use in patients with metastatic castration-sensitive prostate cancer (mCSPC), marking a step forward for the drugmakeFood and Drug Administraton,r’s prostate cancer franchise. 4 June 2025
Pharmaceutical
The UK risks losing £11 billion ($14 billion) in pharmaceutical R&D investment by 2033 unless urgent reforms are made to high and unpredictable clawback payments imposed on medicine sales to the National Health Service, according to a new report commissioned by the Association of the British Pharmaceutical Industry (ABPI). 3 June 2025
Biotechnology
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved SFL Pharmaceuticals Deutschland’s Aumseqa (aumolertinib) for adults with non-small cell lung cancer (NSCLC). 3 June 2025
Pharmaceutical
Shares in MaaT Pharma, a French microbiome company in oncology, closed 25% higher Tuesday. 3 June 2025
Generics
German drugmaker STADA Arzneimittel has reported record earnings on revenues growth in its financial first quarter. 3 June 2025
Pharmaceutical
Germany-based mental health specialist atai Life Sciences is to buy privately-held UK psychedelic drug developer Beckley Psytech in an all-share transaction subject to pre-agreed BPL-003 (mebufotenin benzoate) Phase IIb success criteria. 3 June 2025
All news
Biotechnology
Privately-held Remedy Plan Therapeutics, a US pharma company developing novel, hyperbolic NAMPT inhibitors, has raised more than $18 million in an oversubscribed insider financing round. 13 May 2025
Pharmaceutical
They are the two drugs of the moment, the weight loss products promising a miraculous solution to obesity and—in data presented by Eli Lilly—they have gone up against one another. 13 May 2025
Biotechnology
Swedish biotech Hansa Biopharma has appointed Maria Törnsén as chief operating officer and president US, strengthening its commercial leadership ahead of key milestones for its kidney transplant drug Idefirix (imlifidase). 13 May 2025
Pharmaceutical
Denmark’s Novo Nordisk has presented data at the European Congress of Obesity (ECO) showing that Wegovy (semaglutide injection) 2.4 mg reduced the risk of major adverse cardiovascular events (MACE) by 37% in adults with overweight and obesity and cardiovascular (CV) disease, compared to placebo, on top of standard of care, within the first three months of treatment. 13 May 2025
Generics
India has declined the UK's request to include a 'data exclusivity' clause in the proposed Free Trade Agreement (FTA), as announced on May 6, underscoring its commitment to protect its robust domestic generic drug industry. India's generic drug industry is valued at over $30 billion. 13 May 2025
Pharmaceutical
Swedish contract development and manufacturing firm Recipharm and France-based regulatory specialist ProductLife Group (PLG) have joined forces in a move aimed at speeding up the route to clinical trials and approvals for pharma and biotech companies. 13 May 2025
Pharmaceutical
US biotech Genentech and its parent, Swiss pharma giant Roche, have announced plans to invest more than $700 million in a new 700,000 square foot state-of-the-art drug manufacturing facility in Holly Springs, NC. 13 May 2025
Pharmaceutical
German life sciences company Bayer presented its first-quarter financial results and latest guidance for 2025 on Tuesday. 13 May 2025
Pharmaceutical
US pharma stocks regained ground Monday after Donald Trump signed an executive order aiming to slash prescription drug prices, a move that initially rattled investors but left many analysts unconvinced about its impact. 13 May 2025
Pharmaceutical
Hungary’s largest drugmaker Gedeon Richter has announced its financial results for the first quarter of 2025, sending its shares up 2.2% to 26.46 euros. 13 May 2025
Pharmaceutical
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved Adzynma (apadamtase alfa/cinaxadamtase alfa; rADAMTS13), the first UK treatment to treat congenital thrombotic thrombocytopenic purpura (CTTP) in patients of all ages. 13 May 2025
Biotechnology
Swiss pharma giant Roche, the Breast International Group (BIG), Institut Jules Bordet Clinical Trials Support Unit and Frontier Science Foundation, today announced statistically-significant final overall survival (OS) results from the phase III APHINITY study in people with human epidermal growth factor receptor 2 (HER2)-positive early-stage breast cancer. 13 May 2025
Biotechnology
Swiss pharma giant Roche is investing $280 million to build a new biopharma manufacturing facility in Shanghai, as it doubles down on its commitment to the Chinese market. 12 May 2025
Pharmaceutical
Spanish dermatology specialist Almirall was the envy of investors on Monday, with its share price closing 10% higher. 12 May 2025
Pharmaceutical
Chinese biotech Minghui Pharmaceutical has sold certain rights to its experimental cancer drug MHB088C to Qilu Pharmaceutical in a licensing deal worth up to $177 million. 12 May 2025
Biotechnology
US pharma firm BioMarin Pharmaceutical saw its shares rise nearly 4% to $61.09 this morning, after it released positive new data for its Voxzogo (vosoritide). 12 May 2025
Pharmaceutical
Japanese drugmaker Shionogi has entered into a joint research agreement with French firm Cilcare for the creation of a new drug pipeline for hearing loss. 12 May 2025
Biotechnology
US healthcare giant Johnson & Johnson has announced new data from the Phase III ICONIC-TOTAL study investigating icotrokinra (JNJ-2113), the first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor. 12 May 2025
Biotechnology
Boston, USA-based biotech Aera Therapeutics, which is harnessing next-generation enabling delivery technologies and precision payloads to unlock the full potential of genetic medicines, today announced the appointment of Paul Conrad as chief business and financial officer. 12 May 2025
Pharmaceutical
Denmark, oncology-based Pharmacosmos today announced that it has assumed the worldwide rights, excluding select Asia-Pacific territories, to the investigational oncology asset lerociclib. 12 May 2025
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze